A Long-term Follow-up Study in Participants Who Received CTX001

NCT04208529 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Beta-Thalassemia
Thalassemia
Sickle Cell Disease
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn
Sickle Cell Anemia

Interventions

BIOLOGICAL: CTX001

Sponsor

Vertex Pharmaceuticals Incorporated

Collaborators

[object Object]